Skip to main content

Table 2 Progression free survival for patients treated with doxorubicin and olaratumab in our study

From: Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland

Group

Median PFS

95% CI

All patients

6.8

5.9–7.7

Liposarcoma

9.6

6.1–13.1

UPS

5.7

3.8–7.6

Leiomyosarcoma

6.2

5.2–7.2

Back to article page

Clinical Sarcoma Research

ISSN: 2045-3329